A new research paper was published in Volume 16 of Oncotarget on July 9, 2025, titled "A novel anti-human CD25 mAb with ...

In relapsing-remitting multiple sclerosis, activation of the peripheral immune system can lead to focal inflammation within the CNS. Over the past three decades, therapeutic development has been ...

The CARES clinical programme is the largest prospective investigation in cardiac AL amyloidosis to date with a total of 406 patients enrolled from 19 countries globally, including 281 patients with ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

The Bioindustry Award, now marking its 9th year, recognizes achievements that have significantly contributed to the development of the bioindustry or are expected to contribute to its future growth.

A new research paper was published in Volume 16 of Oncotarget on July 9, 2025, titled “A novel anti-human CD25 mAb with ...

Astria Therapeutics' Navenibart shows promise in phase 3 trials for hereditary angioedema. Click here to find out why ATXS ...

SOUTH SAN FRANCISCO, CA, USA I July 14, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human ...

Reports DescriptionAccording to the analysis conducted by Custom Market Insights (CMI), the Ultomiris drug market is ...